Main Article Content


A. Mussakhmetov

National center for biotechnology, 13/5,Korgalzhyn road, Astana, Z05K8D5, Kazakhstan

A. Turgimbayeva

National center for biotechnology, 13/5,Korgalzhyn road, Astana, Z05K8D5, Kazakhstan

B. Khassenov

National center for biotechnology, 13/5,Korgalzhyn road, Astana, Z05K8D5, Kazakhstan



Human interferon-gamma (IFN-γ) is an important immune component that protects against pathogens and tumours. The IFN-γ cytokine, the only member of the type II interferon family, is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by Th1 CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells upon the development of antigen-specific immunity. The recombinant production of IFN-γ has significant practical value. Here, we describe the production of recombinant human IFN-γ, the gene of which (hIFNG) was efficiently expressed in E. coli. The hIFNG gene was assembled from synthetic fragments, amplified by PCR, and subsequently cloned into several plasmid vectors. The target gene was cloned into recombinant vectors both with and without a hexa-histidine tag. The Rosetta2 (DE3) E. coli strain was used as the host strain for recombinant protein expression and high levels of synthesis of the recombinant human IFN-γ were achieved by the optimisation of induction conditions. The optimal concentration of isopropyl-β-D-thiogalactopyranoside (IPTG) was found to be 0.005 mM. The recombinant protein was shown to accumulate in the E. coli cells as inclusion bodies, and highly pure recombinant human IFN-γ was obtained by multi-stage extraction with chaotropic agents. Purification was carried out by a combination of anion and cation exchange chromatography using Q- and SP-sepharose.


Interferon-gamma, cytokine, recombinant protein

Article Details


Gray P.W., Leung, D.W., Pennica D. et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature, 1982, vol. 295, pp. 503-508.

Gray P.W., Goeddel D.V. Structure of the human immune interferon gene.Nature, 1982,vol. 298, pp. 859-863.

DeGrado W.F., Wasserman Z.R.,Chowdhry V. Sequence and structural homologies among type I. Annu. Rev. Immunol., 1993, vol. 11, pp. 571-611.

NargesMalek-Sabet, Mohammad Reza Masoumian, Majid Zeinali et al. Production, purification and chemical stability of recombinant human interferon-γ; in lowoxygentension condition: a formulation approach. Preparative Biochemistry and Biotechnology,2013.doi:10.1080/10826068.2012.762716.

Jan N.M.,Ijzermans and Richard L. Marquet. Interferon-gamma: A Review. Immunobiol, 1989, vol. 179, pp. 456-473.

Marina D. Kraaij, Elly J.F. Vereyken, Pieter J.M. et al. Human monocytes produce interferon-gamma upon stimulation with LPS.Cytokine, 2014, vol. 67, pp. 7-12.

Billiau A.,Heremans H., Vandekerckhove F. and Dillen C. Anti-interferon-gamma antibody protects mice against the generalized Shwartzman reaction.Eur. J. Immuno, 1987, vol. 17, pp. 1851.

Petrov S., Nacheva G., Ivanov I. Purification and refolding of recombinant human interferon-gamma in urea–ammonium chloride solution.Protein Expression and Purification,2010, vol. 73, pp. 70-73. doi:10.1016.

Xiao Yan & Sheng Hu & Yi-Xin Guan & Shan-Jing Yao.Coexpression of chaperonin GroEL/GroES markedly enhanced soluble and functional expression of recombinant human interferon-gamma in Escherichia coli. ApplMicrobiolBiotechnol, 2012, vol. 93, pp. 1065-1074. doi 10.1007/s00253-011-3599-2.

Khalilzadeh R., Shojaosadati S.A., N. Maghsoudiet al. Process development for production of recombinant human interferon-γexpressed in Escherichia coli.J. Ind. MicrobiolBiotechnol, 2004, vol. 31, pp. 63-69. doi10.1007/s10295-004-0117.

Hiroshi Yamaguchi and Masaya Miyazaki.Refolding Techniques for Recovering Biologically Active Recombinant Proteins from Inclusion Bodies.Biomolecules,2014, vol. 4, pp. 235-251. doi:10.3390/biom4010235.

S. Abeldenov, S. Kirillov, A. Nurmagambrtova, A. Kiribayeva, D. Silaev, B. Khassenov. Expression, purification and biochemical characterization of recombinant phosphohydrolaseAppa in Escherichia coli.Biotechnology.Theory and practice,2014, vol. 3, p. 61.

Yongzhen Xia, Wenqiao Chu, Qingsheng Qi and LuyingXun. New insights into the QuikChangeTM process guidethe use of Phusion DNA polymerase for site-directed mutagenesis.Nucleic Acids Research, 2015, vol. 43, no. 2.doi: 10.1093/nar/gku1189.

Bradford M.M. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal.Biochem., 1976, vol. 72, pp. 248-254.

Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature, 1970, vol. 227, pp. 680-685.

Fomsgaard A., Freudenberg M.A., Galanos Ch. Modification of the silver staining technique to detect lipopolysaccharide in polyacrylamide gels.Journal of clinical microbiology, 1990,vol. 28, pp. 2627-2631.

Fenfen Zhu, Qi Wang, Hefang Pu et al. Optimization of soluble human interferon-γ production in Escherichia coli using SUMO fusion partner. World J MicrobiolBiotechnol, 2013, vol. 29, pp. 319-325. doi10.1007/s11274-012-1185-0.

Tileva M., Krachmarova E., Ivanov al. Production of aggregation prone human interferon gamma and its mutant in highly soluble and biologically active form by SUMO fusion technology.Protein Expression and Purification,2016, vol. 117, pp. 26-34.

JafarMohammadian-Mosaabadi, HosseinNaderi-Manesh, Nader Maghsoudi et al. Improving purification of recombinant human interferon-γ expressed in Escherichia coli; eVect of removal of impurity on the process yield. Protein Expression and Purification, 2007, vol. 51, pp. 147-156.

Jamie R. Schoenbornand Christopher B. Wilson.Regulation of Interferon-gamma during innate and adaptive immune responses.Advances in Immunology, 2007, vol. 96.doi: 10.1016/S0065-2776(07)96002-2.